Literature DB >> 26451296

High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools.

Mathieu F Chevalier1, Sara Bobisse2, Carla Costa-Nunes3, Valérie Cesson1, Patrice Jichlinski1, Daniel E Speiser3, Alexandre Harari2, George Coukos4, Pedro Romero3, Denise Nardelli-Haefliger1, Camilla Jandus3, Laurent Derré1.   

Abstract

In immune intervention trials, the comprehensive investigation of immunogenicity or T-cell epitope-mapping is challenging especially when a large set of epitopes needs to be screened and limited sample material is available. To this end, T-cell responses are often monitored using peptide pools. Here, we assessed the magnitude and sensitivity of detection of antigen-specific CD8+ and CD4+ T cells using a single peptide alone or mixed into large pools. Interestingly the magnitude of ex vivo anti-viral and anti-tumor T-cell responses was identical irrespective of the presence and number of irrelevant peptides, in different functional assays with PBMCs from healthy donors and cancer patients. Moreover, the presence of up to 300 irrelevant peptides did not affect the threshold of responsiveness of antigen-specific CD8+ T cells to single cognate peptides. These data demonstrate the relevance of using very large peptide pools for the sensitive and specific immune-monitoring of epitope-specific T cells in natural or immune-modulated context.

Entities:  

Keywords:  immune monitoring; peptide pools; tumor-associated antigens; tumor-specific T cells; vaccine trials

Year:  2015        PMID: 26451296      PMCID: PMC4590008          DOI: 10.1080/2162402X.2015.1029702

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  27 in total

1.  A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide.

Authors:  Laurent Derré; Mathias Ferber; Cédric Touvrey; Estelle Devevre; Vincent Zoete; Antoine Leimgruber; Pedro Romero; Olivier Michielin; Frédéric Lévy; Daniel E Speiser
Journal:  J Immunol       Date:  2007-12-01       Impact factor: 5.422

2.  A single peptide-major histocompatibility complex ligand triggers digital cytokine secretion in CD4(+) T cells.

Authors:  Jun Huang; Mario Brameshuber; Xun Zeng; Jianming Xie; Qi-jing Li; Yueh-hsiu Chien; Salvatore Valitutti; Mark M Davis
Journal:  Immunity       Date:  2013-10-10       Impact factor: 31.745

3.  T-cell epitope mapping by flow cytometry.

Authors:  F Kern; I P Surel; C Brock; B Freistedt; H Radtke; A Scheffold; R Blasczyk; P Reinke; J Schneider-Mergener; A Radbruch; P Walden; H D Volk
Journal:  Nat Med       Date:  1998-08       Impact factor: 53.440

4.  Identification of HLA-DRB1*1501-restricted T-cell epitopes from prostate-specific antigen.

Authors:  Elena N Klyushnenkova; Jason Link; Warren T Oberle; James Kodak; Cathleen Rich; Arthur A Vandenbark; Richard B Alexander
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

5.  Unexpected low-dose toxicity of the universal solvent DMSO.

Authors:  Joana Galvao; Benjamin Davis; Mark Tilley; Eduardo Normando; Michael R Duchen; M Francesca Cordeiro
Journal:  FASEB J       Date:  2013-12-10       Impact factor: 5.191

6.  Expression of MAGE genes in primary and metastatic cutaneous melanoma.

Authors:  F Brasseur; D Rimoldi; D Liénard; B Lethé; S Carrel; F Arienti; L Suter; R Vanwijck; A Bourlond; Y Humblet
Journal:  Int J Cancer       Date:  1995-11-03       Impact factor: 7.396

7.  Optimizing peptide matrices for identifying T-cell antigens.

Authors:  Melissa L Precopio; Tiffany R Butterfield; Joseph P Casazza; Susan J Little; Douglas D Richman; Richard A Koup; Mario Roederer
Journal:  Cytometry A       Date:  2008-11       Impact factor: 4.355

8.  Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.

Authors:  Camilla Jandus; Gilles Bioley; Danijel Dojcinovic; Laurent Derré; Lukas Baitsch; Sébastien Wieckowski; Nathalie Rufer; William W Kwok; Jean-Marie Tiercy; Immanuel F Luescher; Daniel E Speiser; Pedro Romero
Journal:  Cancer Res       Date:  2009-10-06       Impact factor: 12.701

9.  High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals.

Authors:  M J Pittet; D Valmori; P R Dunbar; D E Speiser; D Liénard; F Lejeune; K Fleischhauer; V Cerundolo; J C Cerottini; P Romero
Journal:  J Exp Med       Date:  1999-09-06       Impact factor: 14.307

10.  Rapid perturbation in viremia levels drives increases in functional avidity of HIV-specific CD8 T cells.

Authors:  Selena Viganò; Felicitas Bellutti Enders; Isabelle Miconnet; Cristina Cellerai; Anne-Laure Savoye; Virginie Rozot; Matthieu Perreau; Mohamed Faouzi; Khalid Ohmiti; Matthias Cavassini; Pierre-Alexandre Bart; Giuseppe Pantaleo; Alexandre Harari
Journal:  PLoS Pathog       Date:  2013-07-04       Impact factor: 6.823

View more
  3 in total

Review 1.  Trial watch: dendritic cell vaccination for cancer immunotherapy.

Authors:  Jenny Sprooten; Jolien Ceusters; An Coosemans; Patrizia Agostinis; Steven De Vleeschouwer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2019-07-18       Impact factor: 8.110

Review 2.  Trial watch: Dendritic cell-based anticancer immunotherapy.

Authors:  Abhishek D Garg; Monica Vara Perez; Marco Schaaf; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-05-12       Impact factor: 8.110

3.  Rapid selection and identification of functional CD8+ T cell epitopes from large peptide-coding libraries.

Authors:  Govinda Sharma; Craig M Rive; Robert A Holt
Journal:  Nat Commun       Date:  2019-10-07       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.